Even the CEOs of Big Pharmas have come under fire. Activist investor Starboard Value has made no secret of its criticism of Pfizer CEO Albert Bourla’s track record, while GSK CEO Emma Walmsley fought ...

Following the official announcement of its administrative restructuring, HCM City has entered a new phase of development, ...

BP's rival, Shell, has expressed interest in a takeover. That would be the least-worst option for Britain’s beleaguered oil ...

Over 20 years, the celebrated law firm has changed more than the market realises—but is it enough in a rapidly transforming global economy? Through insider interviews and data analysis, Law.com ...

Its adoption of generative AI shows the sector is ready for change. Plus, the most innovative law firms over the Innovative Lawyers series ...

FTSE 100 closes down 40 points; Babcock impresses with results, first buyback and raised outlook; FCA proposes review of UK ...

Phase 1 and interim phase 2 data met GSK’s immunogenicity success criteria, the London-based drugmaker said. Yet, GSK has decided to hand off to India’s Bharat for the phase 3 trial.

The first half of 2025 has been marked by a surge in strategic activity across the global healthcare, life sciences, and ...

Bharat Biotech joins GSK to develop a Shigella vaccine to fight shigellosis in children, with Phase 3 trials underway and focus on low-income countries.